Outcome of Topiramate in Migraine Prophylaxis

Abstract Background: Topiramate is an anti epileptic medication originally and one of the first line drugs for migraine prophylaxis.Objective: To assess outcome of Topiramate in migraine prophylaxis by evaluating reduction in frequency and/or severity of attacks and address most common adverse affect associated with it.Methods: A Descriptive, prospective hospital based study was conducted at Ibrahim Malik Hospital, National center of neurological disease and sciences within the period of October 2018 –May 2019. Data entered, cleaned, analyzed using SPSS version 25.0.Results: This study covered 32 study participants; the mean age (33 ± 10) years, with female predominance by 27 (84%).Nearly, half of them 15(47%) migraine triggered by weather changes, 13 (41%) menstruation. 17(53%) was suffering from headache > 24 months, and most of them 26(81%) used the OTC medications in the acute pain headache.Mean of frequency of attacks per month was reduce (6.1 base line to 3.2), in severity mean was (6.9 turn to 5). Reduction in Frequency of attacks there was significant in both number and severity (p value < 0.001) with no significant difference in (50 mg and 100mg dose). Concerning adverse effects 5(15.6%) didn’t complain of any, more than third 12(38%) experienced weight loss, 7(22%) both Abdominal/GIT symptoms and Dizziness, 5(16%) mood changes, 4(13%) both parathesia and decreased memory, 3(9%) both Anorexia and sleepiness.Conclusion: Topiramate is effective in reducing headache frequency and reasonably well tolerated in adult Sudanese patients with episodic migraine. This may provide good evidence to support its use in routine clinical management.

Download Full-text

Socio Demographic Profile and Risperidone Response in New Versus Old Schizophrenia Patients

Journal of Nepalgunj Medical College ◽

10.3126/jngmc.v18i1.35208 ◽

2020 ◽

Vol 18 (1) ◽

pp. 82-85

Author(s):

Mohan Belbase ◽

Jyoti Adhikari

Keyword(s):

Negative Symptoms ◽

Total Duration ◽

P Value ◽

Base Line ◽

Age Group ◽

Old Patients ◽

Syndrome Scale ◽

Significant Difference ◽

The Mean ◽

Negative Syndrome

Introduction: Schizophrenia is a mental disorder characterized with disorganized thinking, perception, expression of reality with significant social and occupational dysfunction. Two groups of drugs are in recent use namely first generation (typicals) and second generation (atypical) antipsychotics. Risperidone is a broad spectrum antipsychotic and has a role as a first-line agent for first break, mild to moderately ill patients and for severely ill treatment–refractory patients. Aims: This article tries to compare the risperidone response in newly diagnosed schizophrenia patients versus old patients already on some antipsychotics other than risperidone. Methods: This is an experimental intervention study of patients attending to psychiatry OPD and indoor in Nepalgunj Medical College, Kohalpur. Total 40 patients (27 new and 13 old) were selected and sample was collected in one year from January 2018 till December 2018. Positive and negative syndrome scale questionnaire was used to record the positive and negative symptoms of schizophrenia on baseline (week 0). Patients were followed up on week 4 and week 8 and the same positive and negative syndrome scale questionnaire was applied to record the improvement. Risperidone was given in therapeutic dose (4-8mg) on the basis of symptoms and improvement. Results: The study subjects were divided into new N=27 (17 male and 10 female) and old N=13 (7 male and 6 female). Maximum number of schizophrenia cases were in age group 15-25 and 35-44 years comprising 30 % in each group. Mean total duration of illness in new group was 23.89 ± 29.51 months (median being 12.0 months) while in old group it was 123.69 ± 83.34 months (median being 96.0 months) with significant difference between two groups (p= <0.001).The mean risperidone dose in milligram on base line (week 0) was 4.15 ± 0.55 for old group while it was 4.04 ± 0.52 for new group. On week 4, the mean dose for old group was 5.08 ± 0.95 while for the new group it was 4.81 ± 1.08. On week 8, the dose for old group was 6.08 ± 1.32 while it was 5.15 ± 1.35 for new group. There was a significant difference in the drug dose on week 8 between old group and new group with p value of 0.047 (statistically significant). Conclusion: Our study suggests that schizophrenia is found in most productive age group. Risperidone is effective in both new and old schizophrenia patients however old patients need higher dose of risperidone than new patients.

Download Full-text

The Clinical Impact of Mild Hemophilia A, Report of a Cohort Study.

Blood ◽

10.1182/blood.v106.11.3210.3210 ◽

2005 ◽

Vol 106 (11) ◽

pp. 3210-3210 ◽

Cited By ~ 1

Author(s):

Mary-Frances Scully ◽

David MacGregor ◽

Meghan Walsh ◽

Brendan Barrett ◽

Marc Kawaja ◽

...

Keyword(s):

Factor Viii ◽

Range Of Motion ◽

General Health ◽

Hemophilia A ◽

P Value ◽

Base Line ◽

Role Emotional ◽

Left Ankle ◽

Sf 36 ◽

Significant Difference

Abstract Due to a founder affect certain regions of the Canadian province of Newfoundland and Labrador have a very high prevalence of mild Hemophilia A. To accurately plan for future health related needs of these patients, a base-line cross-sectional study of a large cohort segregating a known founder mutation (Val2016Ala) was undertaken. Characteristics of Study Participants Characteristic Affected Males Control Males P-Values (Affected vs Control) Carrier Females Control Females P-Value (Carrier vs Control) Values are expressed as number, mean*, median(interquartile range)†, or percentage Overall N 61(5–76yrs) 44(4–81yrs) 0.883 88(8–88yrs) 65(16–78yrs) 0.935 Factor VIII* 0.15(0.05) 1.29(0.37) <0.001 0.78(0.31) 1.34(0.41) <0.001 Hepatitis Bc Antibodies 15.8%(9/57) 0%(0/28) 0.012 0%(0/75) 0%(0/58) - Hepatitis C Positive 19.7%(12/61) 0%(0/33) 0.001 0%(0/88) 0%(0/65) - HIV Positive 1.6%(1/61) 0%(0/33) 0.420 0%(0/88) 0%(0/65) - Diabetes 24.4%(11/45) 6.1%(2/33) 0.031 - - - BMI†(Adults Only) 30.0(27.0–33.0) 27.0(26.0–30.0) 0.028 29.0(20–57) 28.0(19–46) .446 Statistically Significant Difference SF-36 & Colorado PE-05 Mean Scores for Affected and Unaffected Males Affected Males Affected Males Affected Males Unaffected Siblings Unaffected Siblings Unaffected Siblings t-test Difference vs References Dimension n Mean SD n Mean SD P-Value P<0.05)* Affected Males(age 23–76 years) Unaffected Siblings(age 20–81 years) SF-36 Scores General Health Scale 44 58.1 28.7 32 71.4 21.4 0.024* Role Emotional 44 89.2 19.9 33 98.0 5.5 0.007* Colorado PE-05 Musculoskeletal Scores Axial Deformity 47 0.9 1.4 33 0.2 0.8 0.008* Range of Motion 47 4.2 2.0 33 2.9 1.8 0.005* Gait 47 2.4 3.5 33 0.4 1.4 0.002* Left Ankle 47 3.3 5.0 33 1.0 2.9 0.015* Right Ankle 47 3.2 4.6 33 0.7 1.3 0.002* There was a positive association between the SF-36 General Health Scale scores and the following values of the Colorado PE-05 Scores. Gait (R -.45, p<.001), Range of Motion (R-.08, P=.508), Axial Deformity (R -.35, P<.001), Right Ankle (R -.42, p<.001), and Left Ankle (R-.49, p<.001). The association between the SF-36 Role Emotional Scales for affected males and the values of the Colorado PE-05 was also positive. Gait (R -.52, P<.001), Range of Motion (R - .30, P = .01), Axial Deformity (R -.54, P<.001), Right Ankle (R -.06, P<.001) and Left Ankle (R-.52, p<.001). No patients studied have acquired an inhibitor to Factor VIII. Obese males (BMI >30) had significantly greater impairment in their Range of Motion than non-obese males (4.59 vs (3.34), p<0.05) independent of whether or not they had hemophilia. These results are consistent with our clinical experience that mild Hemophilia A causes episodic bleeding, lack of recognition and delayed treatment leads to significant morbidity. The association with diabetes was unexpected. Future interventions will now focus on prevention and early treatment of ankle bleeds and will include strategies to reduce the risk of obesity.

Download Full-text

Assessment of Gingival Health Status among Patients with Fixed Orthodontic Appliance

Polytechnic Journal ◽

10.25156/ptj.v11n1y2021.pp38-41 ◽

2021 ◽

Vol 11 (1) ◽

pp. 38-41

Author(s):

Shahida R. Hussein ◽

Bayan A. Hassan

Keyword(s):

Mean Value ◽

P Value ◽

Orthodontic Appliances ◽

Base Line ◽

Orthodontic Appliance ◽

Gingival Health ◽

Fixed Orthodontic Appliances ◽

Significant Difference ◽

The Mean ◽

Fixed Orthodontic Appliance

Fixed orthodontic appliances corrupt plaque removal, proper oral hygiene, and gingival health so periodontal evaluation is important to be checked in every appointment. The aim of the present study was to assess gingival health among patients with a fixed orthodontic appliance. A clinical comparative study conducted on 25 patients with an aged ranged from 15 to 25 years. Clinical parameters included plaque index (PI), gingival index (GI), and bleeding on probing (BOP) were recorded at base line before starting orthodontic treatment and after 1 month of treatment. A double paired t-test was applied to the data collected for statistical analysis. The mean value of PI (1.11), GI (1.155), and BOP (0.600) scores was increased after placement of fixed orthodontic appliance, but with no statistically significant difference with base line for PI (P-value = 0.596), GI (P-value = 0.355), and BOP (P-value = 0.256), respectively. Regarding age group, mean PI (1.46), GI (1.22), and BOP (0.875) were increased with increasing age, patients who age’s ≥20 showed statistical significant difference for gingival and plaque means P-value = 0.006 and P-value = 0.03) for ≥20, respectively. The finding of this study had shown that patients with fixed orthodontic appliances had non-significant increase in the mean value of plaque, gingival, and BOP indices scores. All mean scores were increased with increasing age, but with non-significantly for BOP only.

Download Full-text

Comparison of Covid-19 IgG Anti-Spike Antibody Titer after Vaccination with Sputnik V in Seropositive and Naïve Vaccinees

Proceedings of Shaikh Zayed Medical Complex Lahore - October to December ◽

10.47489/pszmc-815354-1-5 ◽

2021 ◽

Vol 35 (4) ◽

pp. 1-5

Author(s):

Hajra Farooq

Keyword(s):

Single Dose ◽

Antibody Titer ◽

Immunological Response ◽

Severe Infection ◽

P Value ◽

Igg Antibody ◽

Policy Makers ◽

Significant Difference ◽

Antibody Titers ◽

Study Participants

Introduction: Immunity to SARS-CoV-2 has shown to reduce the risk of having a severe infection and initiate a good degree of disease protection. Studies assessing the antibody titer after vaccination can be very helpful to see whether previously infected individuals have better immunological response as compared to uninfected or antibody naïve individuals. Aims & Objectives: Comparison of Anti-spike IgG antibody among vaccinees with or without previous exposure to COVID-19. To determine whether single dose regimen can produce significant antibody titer amongst previously infected cases and design vaccine dosage regimens accordingly. Place and duration of study: This study was conducted at Chughtai Institute of Pathology from April 2021 to June 2021. Material & Methods: Blood samples were collected from 83 adult male and female vaccinees at baseline, 3 weeks after the first dose and finally 7 days after the second dose. Previously infected individuals’ record was noted separately. Samples were immediately analyzed using Abbott SARS-CoV-2 IgG II quant two step immunoassay. Data was analyzed using SPSS 23.0. A p-value of <0.05 was considered significant.Results: Majority of the candidates (57 %) were females and on analysis it was found that 42% of the patients were seropositive whereas 58% of the patients were antibody naïve before receiving the first dose of vaccine. There was a significant difference between mean antibody titer of seropositive and seronegative study participants at day 0, day 21 and finally on day 28 (p value <0.001) with seropositive individuals having higher antibody titers even after first vaccine shot. Conclusion: Post vaccination immunological response was higher in seropositive individuals as compared to the antibody naïve and this finding can help the policy makers to design a single dose vaccine regimen for the former category.

Download Full-text

Trastuzumab associated cardiotoxicity: Who is at risk?

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e11518 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e11518-e11518 ◽

Cited By ~ 1

Author(s):

Omalkhair A. M. Abulkhair ◽

Ahmed Gasmelseed ◽

Shabab Al Otaibi

Keyword(s):

Breast Cancer ◽

Retrospective Review ◽

Metastatic Breast ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

P Value ◽

Base Line ◽

Ventricular Ejection Fraction ◽

Metastatic Setting ◽

Significant Difference

e11518 Background: Trastuzumab is an important agent in the treatment of both adjuvant and metastatic breast cancer with known cardio toxicity. Cardio toxicity is defined as reduction in left ventricular ejection fraction (LVEF) of > 5% with signs and symptoms of heart failure (HF) or > 10% without such symptoms. Methods: Retrospective review of all breast cancer patients treated in King Abdulaziz Medical City with trastuzumab for adjuvant and metastatic setting from 2003 to 2012. 150 cases were identified, patients with good quality echocardiogram and base line LVEF > 55% were included (104). Patients had base line, then 3 monthly echocardiogram thereafter. Results: Studied patients showed that median age was 49 (43 - 58) years. There was a relevant decline in LVEF in 16 patients (15.38%), after mean exposure duration of 15 months. The study also revealed significant difference in EF decline between diabetic and non diabetic receiving herceptin (31.82% and 10.98% respectively, p-value 0.0213), and in 64.71% with hypercholesrolemia compared to 5.75% in those with normal cholesterol (p-value 0.0001). Conclusions: Given the limitations of this small retrospective review, we have shown that the prevalence of cardio toxicity in our patients is higher than published figures. Also, we have shown a significant correlation between diabetes, hyperlipidimia and cardio toxicity in trastuzumab treated patients. Such patients might need to be closely monitored for cardio toxicity.

Download Full-text

Frequency of Postpartum Haemorrhage after Administration of Per-Rectal Misoprostol in Females Undergoing Vaginal Delivery

Annals of King Edward Medical University ◽

10.21649/akemu.v24i1.2449 ◽

2018 ◽

Vol 24 (1) ◽

pp. 659-664

Author(s):

Mumtaz Akhtar ◽

Iffat Naheed ◽

Khadija Waheed ◽

Raana Mazhar

Keyword(s):

Blood Loss ◽

Vaginal Delivery ◽

Postpartum Haemorrhage ◽

Low Frequency ◽

Normal Vaginal Delivery ◽

P Value ◽

Obstetrics And Gynaecology ◽

Significant Difference ◽

The Mean ◽

Study Participants

Abstract | This study was designed to determine the frequency of postpartum hemorrhage after administra-tion of per rectal misoprostol in females undergoing normal vaginal delivery. The study was conducted at the Department of Obstetrics and Gynaecology, Teaching Hospital, Lahore from 02-09-2014 to 03-03-2015.Non-probability and purposive sampling techniques were used. A total of 220patients undergoing normalvaginal delivery at term after administration of per rectal misoprostol were enrolled with 95% confidenceinterval (C.I). The error margin was 5% and the prevalence of postpartum haemorrhage was 16.5%. Datawas entered and analyzed through SPSS 17. In this study, the mean age of study participants was found tobe 29.89±5.89 years while the mean gestational age was 38.86±1.38 weeks. Postpartum haemorrhage wasobserved in 35.45% cases. Blood loss was recorded in patients with a mean of 374±134.91 mL. Statistically,a highly significant difference was observed between the blood loss and postpartum haemorrhageamong the patients (i.e. p-value=0.000). A low frequency of postpartum hemorrh agein women experiencing normal vaginal delivery after misoprostol was administered. The blood loss was recorded to be very low among females.

Download Full-text

A prospective study of correlation between smoking and serum calcium in newly diagnosed essential hypertension

International Journal of Advances in Medicine ◽

10.18203/2349-3933.ijam20201115 ◽

2020 ◽

Vol 7 (4) ◽

pp. 639

Author(s):

Chandra Babu S. ◽

Venkata Ravi Kumar Chepuri ◽

Sireesha Ella

Keyword(s):

Essential Hypertension ◽

Parathyroid Hormone ◽

Serum Calcium ◽

Health Hazard ◽

P Value ◽

Base Line ◽

Newly Diagnosed ◽

Significant Difference ◽

The Government ◽

A Prospective Study

Background: Smoking significantly reduces the vitamin D and serum parathyroid hormone levels. But no significant difference was observed in serum calcium levels in previous studies. Some studies showed significantly low serum calcium levels in essential hypertension. There are limited international and local studies about the effect of cigarette smoking on the levels of serum calcium in relation to hypertension. Our study aims to find correlation between smoking and serum calcium in newly diagnosed essential hypertensive patients.Methods: Total 70 cases of newly diagnosed essential hypertension who attended the outpatient department at the government general hospital were included in this study based on inclusion criteria. Base line data including age, gender, risk factors were obtained. Blood biochemistry including serum calcium levels were obtained at the time of diagnosis and results were analysed.Results: Among 70 cases of essential hypertension there were 24 smokers and 46 nonsmokers. Serum calcium was found low in 37 cases of essential hypertension. Out of 37, 12 were smokers and 25 were nonsmokers, p value is 0.6981 and it is not significant.Conclusions: Smoking is a major health hazard, with detrimental effects on many organs. In our study serum calcium was significantly less among Hypertensives and correlated inversely with blood pressure. But there was no significant difference in serum calcium among smokers and nonsmokers. Measuring the level of parathyroid hormone in cigarette smokers, may help to clarify the finding in present study.

Download Full-text

Statin and Post-Cardiac Surgery Atrial Fibrillation Prevention: Systematic Review and Meta-analysis

10.22541/au.163655013.32285028/v1 ◽

2021 ◽

Author(s):

Federico Oliveri ◽

Andrea Bongiorno ◽

Sara Compagnoni ◽

Alessandro Fasolino ◽

Francesca Gentile ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cardiac Surgery ◽

Fixed Effects ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

P Value ◽

Fixed Effects Model ◽

Significant Difference ◽

Pre Treatment ◽

Study Participants

Introduction: Postoperative atrial fibrillation (POAF) is a frequently reported complication of cardiac surgery, leading to increased in-hospital and long-term mortality rates. Many studies have suggested using statins to protect against POAF. Thus, we aim to investigate if statin pre-treatment may effectively lower the incidence of POAF. Method: We performed a systematic literature search of PubMed for potential studies between January 2006 and August 2021. Principal inclusion criteria were: randomized clinical trials study design; statin-naive patients; total study participants ≥ 50 units. We used the fixed-effects model to obtain the odds ratio (OR) and 95% confidence interval (CI) for each analyzed intervention. Results: Overall, statin pre-treatment reduced the incidence of POAF compared to placebo (OR 0.71; 95% CI: 0.60-0.85, p-value < 0.00001). Analyzing subclasses, atorvastatin was associated with lower incidence of POAF (OR 0.54; 95% CI: 0.41-0.70, p-value = 0.002), but rosuvastatin was not (OR 0.90; 95% CI: 0.71-1.14, p-value = 0.38). Selecting studies with ≥ 199 patients, results were divergent. There was not statistically significant difference between statin pre-treatment and placebo (OR 0.89; 95% CI: 0.74-1.09, p-value = 0.26), as well as for atorvastatin (OR 0.74; 95% CI: 0.54-1.03, p-value = 0.08) and rosuvastatin (OR 0.87; 95% CI: 0.68-1.12, p-value = 0,29). Conclusion: Statin pre-treatment before cardiac surgery is not associated with a significant reduction in POAF occurrence. Thus, based upon our results and considering possible renal complications, we discourage statin pre-treatment in preventing POAF.

Download Full-text

Comparative Efficacy of the Combination of Topical Betamethasone Dipropionate and Calcipotriene with Betamethasone Dipropionate and Calcipotriene Alone in the Treatment of Localized Vitiligo

Medicine Today ◽

10.3329/medtoday.v26i1.21310 ◽

2014 ◽

Vol 26 (1) ◽

pp. 31-35

Author(s):

Mohd Nurul Alam ◽

Md Abdul Wahab ◽

Md Anwar Husain ◽

Lubna Khondker ◽

Gulam Kazem Ali Ahmad ◽

...

Keyword(s):

Betamethasone Dipropionate ◽

Ordinal Scale ◽

P Value ◽

Base Line ◽

Anova Test ◽

Global Estimate ◽

Significant Difference ◽

Group A ◽

Group B

Vitiligo is an acquired skin disorder characterized by welldefined white patches that are often symmetrically distributed. The study was conducted to compare the efficacy of the combination of topical betamethasone dipropionate and calcipotriene with betamethasone dipropionate and calcipotriene alone in the treatment of localized vitiligo. A clinical trial was carried out with the patients of vitiligo from January 2012 to August 2012. In group A, 20 patients were applied betamethasone dipropionate cream 0.05% and topical calcipotriene ointment (0.005%), in group B, 20 patients were applied betamethasone dipropionate cream 0.05% only; In group C, 20 patients were applied calcipotriene ointment 0.005% alone. From base line percentage reduction of total lesion in 1st follow up in group A, group B and group C were 20%, 15% and 10% respectively. At 3rd follow up in group A, group B and group C it was 50%, 37% and 30% and at 5th follow up, it was 80%, 75% and 65% respectively. ANOVA test was done and found significant difference of reduction of total lesion of vitiligo among the groups (p< 0.05). At the completion of the study, each patient was separately graded the treated sides on a 6-point ordinal scale based on a global estimate of the change in vitiligo and found that, the very much improvement were 70%, 55% and 45%, much improvement were 20%, 30% and 35% and improvement were 10%, 15% and 20% in group A, group B and group C respectively. ANOVA test was found significant difference of success rate of patients of localized vitiligo among the groups (p value 0.005). Both the drugs, calcipotriene and betamethasone dipropionate when used individually, were found to be equally effective in the treatment of vitiligo, but the combination of the two was found to be superior in efficacy. DOI: http://dx.doi.org/10.3329/medtoday.v26i1.21310 Medicine Today 2014 Vol.26(1): 31-35

Download Full-text

Association of migraine severity and disability with body mass index.

The Professional Medical Journal ◽

10.29309/tpmj/2020.27.05.4012 ◽

2020 ◽

Vol 27 (05) ◽

pp. 979-986

Author(s):

Kavita Bai ◽

Ramesh Kumar Suthar ◽

Pushpa Goswami ◽

Mumtaz Ali Memon

Keyword(s):

Body Mass Index ◽

Body Mass ◽

Migraine With Aura ◽

Age Of Onset ◽

Ethical Review ◽

Future Research ◽

P Value ◽

Waist Hip Ratio ◽

Significant Difference ◽

Study Participants

Objectives: To explore the association of migraine severity and disability with body mass index. Study Design: Cross sectional study. Setting: Department of Medicine and Physiology of Indus Medical College, Tando Muhammad Khan. Period: August 2018 and March 2019. Material & Methods: It included all patients both female and male diagnosed with migraine of age group 18-55 years. Diagnosis of migraine was done according to the guidelines by international headache society. Approval was taken from the ethical review committee of the Institute. Severity of migraine was evaluated according to MIDAS questionnaire obesity was determined from Body mass index (BMI). Patients were divided into four groups according to various body mass index categories as per the revised guidelines into underweight: m2, Overweight: 23.0-24.9 kg/m2, Obesity: >25 kg/ m2. Clinical features of migraine were compared in these groups. The collected data was analyzed in SPSS version 18.00. Results: A total 189 (n=189) participants recruited in this study, meeting selection criteria were included. Out of 189, 73 presented with aura while 116 presented without aura. So the study population divided into two groups one wit aura (n=73) and other without aura (n=116). The overall mean age + SD (range) was 28.80+ 8.54(18 to 48 years). There was no significant difference of age (compare means) between male and female subjects (p value = 0.99). The study participants (n=189) divided into two types, first migraine with Aura n=73 (38.62%) and second Migraine without aura n=116 (61.36%). Mean±SD of MIDAS score, waist hip ratio, age of onset of headache (in years), frequency of headache per month and the duration of headache (in hours), of the study participants were 12.18+4.48, 0.87+.066, 18.89+2.97, 10.93+2.70 and 67.32+12.52 respectively. Mean±SD of MIDAS Score among the miranieuers without aura (n=116) was 12.18±4.48 but among the patients who presented with aura (n=73), it was 16.39±6.39. (P value<0.01) that presents statistically significant association of the type of migraine with MIDAS score. Out of 189 migraine patients (n=189), 30(15.87%) were with normal BMI, 11(5.82%) were underweight, 111(58.73%) were overweight and remaining 37(19.58%) were obese. Mean of the MIDAS score among normal BMI (n=30), underweight (n=11), overweight (n=111) and obese (n=37), when compared by applying ANOVA test; MIDAS score among these four groups were 11.43, 11.18, 10.81 and 17.18 respectively. (f value 27.3 and p value 0.001). That reveals the significant disability and disturbed quality of life among the migraineurs who are overweight and obese. Similarly, when mean ±SD of the duration of headache (in hours) compared among normal BMI (n=30), underweight (n=11), overweight (n=111) and obese (n=37), it was 66.06±10.70, 58.9091±15.62, 66.64±9.01 and 72.86±18.82 respectively. (p value 0.004 and f value 4.52) that is statistically significant. Duration of headache he was more among obese migraine patients. When Body mass index evaluated according to type of migraine, among the migraine patients without aura (n=116), 18 (60%) were of normal BMI, 8(72.7%) of underweight BMI, 89(80.2%) were overweight and 1 (2.7%) was obese. Instead, among the migraine patients with aura, 12(40.0%) were of normal BMI, 3(27.3%) of underweight, 22(19.8%) were overweight and 36(97.3%) were obese. P value <0.001 with Pearson chi aquare value 70.910a When MIDAS grade compared among the patients with aura (n=116) and without aura (n=37) there was significant difference of MIDAS grade between these two groups. (p value 0.005) Waist hip ratio was more among the patients of migraine with aura when compared with the patients without aura. (P value <0.01). Conclusion: This study demonstrates that there is strong positive association between the severity and disability due to migraine with increase in body nass index. Future research is required to fill the gap to explore the pathophysiologic mechanisms beside this association.

Download Full-text